AbbVie Inc. is 266.9x more valuable than Amylyx Pharmaceuticals, Inc. by market capitalization ($399.47 B vs $1.50 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AMLX | ABBV |
|---|---|---|
| Market cap | $1.50 B | $399.47 B |
| US-listed rank | #2318 | #28 |
| Revenue (latest FY) | $0.00 | $61.16B |
| Net income (latest FY) | -$144.74M | $4.23B |
| Net margin | - | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 403 | 1,008 |
AbbVie Inc. is 266.9x more valuable than Amylyx Pharmaceuticals, Inc. by market capitalization ($399.47 B vs $1.50 B).
In their latest fiscal years, Amylyx Pharmaceuticals, Inc. reported $0.00 in revenue while AbbVie Inc. reported $61.16B.
Full pages: Amylyx Pharmaceuticals, Inc. and AbbVie Inc., or browse the full rankings.